We found that the MC2 subtype with the best prognosis has higher T cell lytic activity and lower angiogenesis, IFNγ, and TIDE scores, indicating that this subtype has stronger immunogenicity and a good tumor microenvironment and is more likely to benefit from immunotherapy. This evidence concerns the gene IFNG and neoplasm.